TRAIL (TNF-related apoptosis-inducing ligand) regulates adipocyte metabolism by caspase-mediated cleavage of PPARgamma
Open Access
- 24 January 2013
- journal article
- research article
- Published by Springer Science and Business Media LLC in Cell Death & Disease
- Vol. 4 (1), e474
- https://doi.org/10.1038/cddis.2012.212
Abstract
Tumor necrosis factor α (TNFα) and other members of the TNF family affect adipose tissue metabolism and contribute to the obesity-related inflammation of adipose tissue. Here, we sought to identify the effects of TRAIL (TNF-related apoptosis-inducing ligand) on fat cell biology. TRAIL-receptor 2 (TRAIL-R2) and its mouse homolog DR5 were regulated upon acute and chronic energy imbalance in murine and human adipose tissue. TRAIL inhibited insulin-stimulated glucose uptake and de novo lipogenesis in human adipocytes. Interestingly, TRAIL did not interfere with the phosphorylation of insulin-stimulated kinases such as Akt or Erk and did not activate the NF-κB pathway. Instead, TRAIL activated cleavage of caspase-8 and caspase-3. The subsequent cleavage of PPARγ led to its inactivation and resulted in reduced expression of lipogenic genes, such as Glut-4, FASN, and ACC. Taken together, we discovered a so far unknown function of the death ligand TRAIL in regulating adipocyte metabolism. Our results imply that TRAIL/TRAIL-R system might provide a new target for the prevention and treatment of obesity and its co-morbidities.Keywords
This publication has 47 references indexed in Scilit:
- Downregulation of FLIP by cycloheximide sensitizes human fat cells to CD95-induced apoptosisExperimental Cell Research, 2011
- The Inflammasome-Mediated Caspase-1 Activation Controls Adipocyte Differentiation and Insulin SensitivityCell Metabolism, 2010
- New insights into apoptosis signaling by Apo2L/TRAILOncogene, 2010
- Deletion of Fas in adipocytes relieves adipose tissue inflammation and hepatic manifestations of obesity in miceJCI Insight, 2010
- c-Jun N-Terminal Kinase 1/2 Activation by Tumor Necrosis Factor-α Induces Insulin Resistance In Human Visceral But Not Subcutaneous Adipocytes: Reversal by Liver X Receptor AgonistsJournal of Clinical Endocrinology & Metabolism, 2009
- Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumorsAnnals Of Oncology, 2009
- Tumor Necrosis Factor-α Induces Caspase-mediated Cleavage of Peroxisome Proliferator-activated Receptor γ in AdipocytesPublished by Elsevier BV ,2009
- Following TRAIL’s path in the immune systemImmunology, 2009
- A gene expression network model of type 2 diabetes links cell cycle regulation in islets with diabetes susceptibilityGenome Research, 2008
- Involvement of TRAIL/TRAIL‐receptors in human intestinal cell differentiationJournal of Cellular Physiology, 2005